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1. Introduction 
The question, “What causes vitiligo?” remains ambiguous. The lay population generally 
accepts that it is the concept of the “autoimmune destruction of pigment-producing cells 
called melanocytes” – however, this assertion has not been fully substantiated. The exact 
pathogenesis is unknown, but research shows that it is complex, involving the interplay of 
multiple factors, many of which are not elucidated. In the last century, much research has 
been dedicated to vitiligo and several overarching theories of its pathogenesis have 
emerged.  
In addition to genetics, the Neural Theory was first proposed by Lerner et al in the 1950s 
(Lerner, 1959), and since then, the Autoimmune Theory, Reactive Oxygen Species Model 
and the Melanocytorrhagy Hypothesis have been developed.  
2. The role of genetics in the pathogenesis of vitiligo 
Numerous studies have investigated the effect genetics engender on the onset and 
development of vitiligo. It is important to recognize the patterns of vitiligo and its physical 
distribution, as the genetic basis for each type of distribution can differ. Trichrome vitiligo 
refers to lesions that appear white, light brown, and dark brown concurrently, with each 
color representing a stage of disease progression. Inflammatory vitiligo lesions present with 
pruritus and have elevated, erythematous margins. Distribution of the disease follows two 
basic patterns: focal vitiligo involves one or several macules at a single site, whereas 
generalized vitiligo (GV) involves a widespread and largely symmetrical distribution of 
macules. When GV becomes extensive, or coalesces to which point the vast majority of the 
body is involved and very few pigmented areas remain, it is deemed vitiligo universalis. Both 
focal and generalized types are considered non-segmental vitiligo, whereas segmental vitiligo 
refers to disease that occurs and remains stable in one unilateral region, but at the same time 
can be associated with lesions elsewhere (Wolff & Johnson, 2009).  
2.1 Family-based studies and patterns of vitiligo inheritance 
Studies demonstrate that a family history for vitiligo exists in 6.25-38% of patients (Njoo et 
al., 2001); however, the exact mode of inheritance remains unclear (Njoo et al., 2001). A study 
by Majumder et al (1988) suggested that recessive alleles at multiple unlinked loci interact 
epistatically to cause the vitiligo phenotype. They employed their own Multiple Recessive 
Homozygosis Model (Li, 1987) with a data set of 274 families that had one affected 
individual to develop this hypothesis (Majumder et al, 1988). The model assumes that 
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vitiligo is a recessive trait, involving multiple, autosomal, and unlinked loci. After applying 
their population data to this model, they found no significant differences between the 
observed segregation probabilities and those calculated using the Multiple Recessive 
Homozygosis Model (1987). These results demonstrate that recessive alleles at multiple 
unlinked loci could be involved in the genetic pathogenesis of vitiligo.  
Years later, researchers tested this hypothesis with another family-based study, gathering 
data on 194 affected families from the United States (Nath et al., 1994). This study showed 
that approximately 20% of affected individuals, or ”probands”, had at least one first-degree 
relative also with vitiligo. After completing segregation analysis of their data, the 
researchers concluded that three epistatically interacting autosomal diallelic loci are 
involved, and individuals who maintain recessive homozygosity at these loci are affected by 
vitiligo (Nath et al, 1994).  
A study examining 1,030 Korean vitiligo patients also demonstrated a clear pattern of familial 
aggregation. Of these patients, 120 had a family history of vitiligo and data from these patients 
was collected. They found clear father-to-son transmission in some families, effectively ruling 
out X-linked inheritance as a possible genetic etiology. If a threshold trait, in this case vitiligo, 
has a multifactorial mode of inheritance, its frequency in relatives of affected individuals 
approaches the square root of the trait’s frequency in the general population. Using their data, 
they calculated that the threshold trait in first-degree relatives of vitiligo patients was similar 
to the square root of the trait’s frequency in the general population. Thus, their findings 
suggest that the inheritance of vitiligo is polygenic (Kim et al, 1999).  
2.2 Molecular genetics-based studies 
Another group studied 102 families with more than one vitiligo-affected offspring (termed 
”multiplex” families) (Spritz et al., 2004). Peripheral blood was collected, and genotyping 
was done on 660 people, and 300 were found to be affected with vitiligo. Following genome-
wide linkage analysis of these individuals, and heterogeneity testing between families with 
autoimmune disorders and families with no history of autoimmune disorders, they 
concluded that, for generalized vitiligo, there are two phenotypic subcategories that involve 
different loci or alleles. For patients with vitiligo and other concomitant autoimmune 
diseases, associated loci include the auto-immune susceptibility (AIS)-1, AIS2 (on 
chromosome 7), and the systemic lupus erythematosus vitiligo-related gene (SLEV1, a locus 
on chromosome 17 that is detected in multiplex families with systemic lupus 
erythematosus). The other phenotypic category, involving patients with generalized vitiligo 
alone, is linked with the AIS3 locus (on chromosome 8) (Spritz et al, 2004).  
In a study of 26 vitiligo patients from Jordan, researchers investigated NALP1 as a 
candidate gene for the pathogenesis of vitiligo (Alkhateeb et al., 2010). NALP1 acts as a 
primary regulator of the innate immune system, primarily existing in Langerhans cells 
and T cells (Kummer 2007). Eight variants within the NALP1 genomic and promoter 
regions were genotyped and analyzed, of which two variants in the NALP1 promoter 
region (rs2670660 and rs1008588) were determined to have significant association with 
vitiligo and Caucasian patients. These results confirm findings by Jin et al in 2007 
demonstrating the association between the single nucleotide polymorphism (SNP) 
rs2670660 and vitiligo in a Romanian population.  
Another means of investigating the genetic basis of vitiligo predisposition is to carry out a 
genome-wide association study. Birlea et al (2011) used genotype data from 1,392 unrelated 
non-Hispanic white vitiligo patients and compared these to 2,629 non-Hispanic white 
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controls to determine genetic associations with GV. Of the thirty-three candidate loci tested, 
only three (FOXP3, TSLP, and XBP1) had a primary association with GV. Whereas the exact 
function of genes TSLP and XBP1 are unknown, FOXP3 is known to be erroneous in the X-
linked recessive multiple autoimmune disease syndrome. Further meta-analysis suggested 
XBP1 is the most significant GV susceptibility locus. Lastly, they determined that the locus 
CTLA4 maintains a secondary association with GV, having its primary association with the 
autoimmune diseases epidemiologically related to vitiligo (Birlea et al, 2011).  
Other studies have gone beyond identifying what genes are involved, to the mechanisms 
behind how the expression of those genes may be modified in order to create the vitiligo 
phenotype. Deoxyribunucleic acid (DNA) methylation is an epigenetic process that plays a 
role in gene transcription and genomic imprinting, among other mechanisms (Li 2002 and 
Reik et al., 2001). The methylation itself is carried out by enzymes called DNA 
methyltransferases (DNMT1, -3a, -3b). Zhao et al (2010) examined peripheral blood 
mononuclear cells (PBMCs) from vitiligo patients and controls, and measured messenger 
ribonucleic acid (mRNA) levels of DNMTs, methyl-DNA binding domain proteins (MBDs) 
and interleukin-10 (IL-10). Since IL-10 has been associated with autoimmune reactivity, and 
demonstrated to be sensitive to alterations in methylation status, its levels were also 
examined (Balasa et al., 1998, Dong et al., 2007, Szalmas et al., 2008). In vitiligo PBMCs, it was 
found that methylation was increased in comparison with controls, and, notably, the 
methylation-sensitive region in IL-10 was hypermethylated. At the same time, IL-10 
expression was significantly reduced in the vitiligo PBMCs. These results suggest that in 
vitiligo, changes in DNA methylation activity can alter the expression of genes involved in 
autoimmunity, thereby providing a potential means for creating the vitiligo phenotype. 
In a similar way, Yun et al (2010) assessed genetic interactions by looking into the 
transforming growth factor beta-receptor II (TGFBR2). This receptor has immunologic 
signaling that may cause autoimmune disease through a variety of mechanisms including 
inhibition of inflammatory pathways and lymphocyte activation (Basak et al, 2009). This was 
performed on a Korean sample that consisted of 415 controls and 233 non-segmental vitiligo 
(NSV) patients that were genotyped. Following age and gender adjustments and data 
analysis, three SNPs for the receptor gene were found to be significantly associated with the 
NSV group, suggesting a possible role for TGFBR2 signaling in the pathogenesis of vitiligo.  
The destruction of melanocytes results in the depigmentation observed in vitiligo. The 
ultraviolet radiation resistance-associated gene, or UVRAG, not only confers UV-damage 
resistance, but has also been demonstrated to play a role in autophagy – the process of 
cellular self-destruction that is potentially tied to autoimmune pathologies (Liang et al., 
2006). For these reasons, Jeong et al conducted a study to investigate a potential UVRAG 
association with NSV, or GV, in a Korean population. With 225 NSV patients and 439 
controls, the researchers identified two SNPs of UVRAG that showed a significant genotype 
difference between the two groups, thereby suggesting a potential association between 
UVRAG and NSV (Jeong et al., 2010). 
Birlea et al (2010) did a genome-wide association study and located notable SNPs at 6q27. 
These SNPs were located near the insulin-dependent diabetes mellitus 8 locus (IDDM8), 
which is an association signal for type 1 diabetes and rheumatoid arthritis. In this study, 32 
distantly related vitiligo patients from a Romanian founder population and 50 healthy 
controls from villages in its vicinity were genotyped. The region on 6q27 where the SNPs 
(specifically rs13208776) are located contains a single gene – SMOC2. This gene encodes a 
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protein whose exact function is unknown, but it is postulated to be involved in growth and 
development (Liu et al., 2009) and cell matrix interactions (Maier et al., 2008).  
Kingo et al (2006) have demonstrated that messenger ribonucleic acid (mRNA) expression of 
melanocyte proliferating gene 1, or MYG1 (a gene involved in early developmental 
processes), is elevated in lesional skin of vitiligo patients. Nine SNPs are found within the 
MYG1 locus for susceptibility to vitiligo (Philips et al., 2010). The MYG1 gene consists of 
seven exons, culminating as 7.5 kilo-base pair (kb) of DNA on chromosome 12. In total, 10 
SNPs are apparent within the gene. The study examined 124 unrelated Caucasian vitiligo 
patients in Estonia. The -119 promoter SNP demonstrated an association with vitiligo. Two 
alleles exist at this SNP, a more common -119C allele and a minor -119G allele. They found a 
higher frequency of the -119G allele in vitiligo patients compared to controls and that this 
increase was most prevalent in patients with active vitiligo. The Kingo et al (2006) study 
found that MYG1 expression was the same in non-lesional skin of non-active vitiligo 
patients and in control skin. In active vitiligo patients, MYG1 expression was increased in 
both lesional and non-lesional skin, and within the lesional skin of non-active vitiligo 
patients. These results taken together thus suggests that the -119G allele of the MYG1 
promoter sequence is a potential risk-allele for developing vitiligo and for the active state of 
the disease (Philips et al., 2010).  
2.3 Studies involving the human leukocyte antigen 
A Chinese study genotyped 1,178 vitiligo patients and 1,743 controls for any association 
HLA-DRB1*07 had with vitiligo, and found that the HLA-DRB1*07 positive group showed a 
significantly higher frequency of early age of onset, positive family history, and vitiligo-
associated autoimmune diseases than that of the negative group (Hu et al, 2010). Another 
study examined the influence of HLA susceptibility on familial versus non-familial vitiligo. 
One hundred and fourteen patients were studied, of which 84 had a family history and 30 
did not. Familial or not, the vitiligo patients demonstrated no significant difference in the 
type, stability, and severity of the disease. Both groups showed an increase in HLA alleles 
A2, A11, A31, A33, B17, B35, B40 and B44. Familial vitiligo was specifically associated with 
increased HLA A2, A28, A31 and B44. The study also demonstrated that vitiligo with onset 
at younger than 20 years old was correlated with increased numbers of HLA A2, A11, B17, 
B35 and B44 (Misri et al, 2009). The latter study suggests that the genetic pathogenesis of 
familial versus non-familial vitiligo is different, albeit possibly overlapping. 
Ying et al (2010) conducted a study genotyping 579,146 SNPs in 1,514 GV patients and 
compared the results with control genotypes. Significant associations included SNPs of 
genes encoding MHC class I (between HLA-A and HCG9) and class II (between HLA-
DRB1 and HLA-DQA1) proteins. SNPs of significance were found in genes related to 
other autoimmune diseases (PTPN22, LPP, IL2RA, UBASH3A, C1QTNF6). The SNPs of 
genes RERE and GZMB (both involved in immunity in general) (Ying et al., 2010), and the 
TYR locus (which encodes tyrosinase, an enzyme required for melanogenesis) (Spritz et 
al., 2003) were also important. Overall, these candidate associations with NSV support the 
assertion that NSV susceptibility loci are shared with loci associated with other 
autoimmune diseases (Ying et al., 2010).  
In another genome-wide association study, susceptibility loci were found on chromosome 
6 and in the MHC (Quan et al, 2010). Genotyping of 6,623 vitiligo patients and 10,740 
controls was carried out, and analyzed for 34 SNPs which deemed promising from a 
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previous study. In the MHC region, two independent association signals were found 
(rs11966200 and rs9468925), the latter of which is potentially a novel HLA susceptibility 
allele. On chromosome 6, two significant SNPS were found at 6q27 in a block containing 
three separate genes. One of these genes, RNASET2, encodes a ribonuclease (RNAse). When 
this gene is overexpressed, it makes cells more vulnerable to oxidative stress (Thompson et 
al., 2009), an important mechanism for melanocyte destruction. The two genes are FGFR10P, 
which encodes a fibroblast growth factor receptor and can play a role in cell cycle 
progression in some disorders (Acquaviva et al., 2009), and the chemokine receptor 6 gene 
(CCR6) (Quan et al, 2010).  
Another HLA-oriented study by de Castro et al (2010) examined the gene encoding the 
discoidin domain receptor 1 (DDR1). This gene encodes a tyrosine kinase receptor that 
affects cell differentiation, adhesion, and cytokine production (Yoshimura et al., 2005). 
One of the three SNPs of DDR1 (rs2267641) was found to be significantly associated with 
vitiligo. No association with autoimmune disorders was observed in this study, which 
suggests that vitiligo susceptibility may or may not be aligned with autoimmune disease 
(de Castro et al., 2010).  
Thus, the genetics behind the pathogenesis of vitiligo appear multifactorial and causal 
associations are yet to be established. 
3. The neural theory 
3.1 Early development and important principles 
Lerner’s "Neural Theory” (1959) asserted that depigmentation in vitiligo results from 
increased discharge of a specific substance (e.g., melatonin) at peripheral nerve endings in 
the skin; one that lightens pigment and discourages formation of new melanin. Lerner went 
on to report that many cases of segmental vitiligo followed a clear dermatomal pattern, and 
that vitiliginous lesions were found to exhibit hyperhidrosis at rest. His study of one 
hundred and twenty-eight vitiligo patients also found that 30% of patients reported 
significant emotional upset preceding onset of disease, and an additional 39% associated 
their onset with nervousness, accidents, illnesses, operations, or parturition. Overall, 69% 
patients associated vitiligo onset with stress (Lerner 1959).  
To establish the role of stress and the onset of vitiligo, Manolache & Benea (2007) did a 
case control study with thirty-two vitiligo patients, forty-five alopecia areata patients, and 
controls suffering from skin disease clearly unrelated to stress (e.g., infection). Data from 
vitiligo and alopecia areata patients were analyzed separately. Sixty-five percent of 
vitiligo patients noted stressful events at disease onset or exacerbation, compared to 
twenty-one percent of age and gender-matched controls. An odds ratio was calculated as 
6.81 with a 95% confidence interval of 2.24-20.71. The majority of vitiligo patients reported 
their stressors were primarily associated with personal and financial issues. Overall, the 
study lends support to the notion that a stressful life event may contribute to the onset or 
exacerbation of vitiligo.  
Koga & Tango (1988) described the clinical picture of vitiligo in 480 patients, and from 
their data they formulated a set of categories to better define the disease. Type A vitiligo is 
associated with autoimmune disease, halo-nevi, and the Koebner phenomenon. It can 
occur at any age, and it progresses continuously with periods of remission and 
exacerbation. On the other hand, Type B vitiligo has an early age of onset, and spreads 
rapidly for a short time and then ceases. More relevant to the neural hypothesis is Type B 
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vitiligo, which spreads over an affected dermatomal area (Koga & Tango, 1988). An 
additional classification germane to the neural theory is segmental vitiligo, in which 
lesions occur in the distribution, or “segment” of one or more nerves, albeit not 
necessarily affecting the entire segmental region (Lerner 1959).  
3.2 Histopathological, microscopic and ultrastructural studies 
Al’Abadie et al (1995) used electron microscopy to examine nerve fibers in the superficial 
dermis from vitiligo and control patients. Biopsies were taken from marginal (i.e., 
peripheral) and central areas of vitiligo lesions as well as non-lesional skin. Vitiligo patients 
consistently demonstrated significantly thicker Schwann cell basement membranes 
surrounding nerve fibers in both lesional and non-lesional vitiligo skin, compared to 
controls. Finally, nerve ultrastructure was not dependent on the location (marginal or 
central) of the vitiliginous lesion. These findings suggest that, although in vitiligo the 
ultrastructural changes of superficial nerves are subtle, there is neural involvement in the 
pathogenesis of vitiligo (Al’Abadie et al., 1995).  
Gokhale & Mehta (1983) further investigated the histopathology of skin from vitiligo 
patients. Their work examined the epidermis, dermal papillations, blood vessels, sweat 
glands, sweat ducts, hair follicles and sebaceous glands, dermal nerve and nerve endings, 
and the connective tissue of the dermis. Seventy-four patients were studied and 
researchers examined biopsies from depigmented areas and contralateral, pigmented 
areas from vitiligo patients and compared these with control biopsies from corresponding 
sites from unaffected individuals (Gokhale & Mehta, 1983). It was observed that more 
acute disease was associated with a high frequency of inflammatory changes and long-
standing disease demonstrated significant degenerative changes in dermal nerves and 
sweat glands. The dermal nerves in 41% of patients were completely degenerated and 
38% showed some degree of degeneration. Similar findings were present at the nerve 
endings. Gokhale & Mehta (1983) concluded that since melanocytes are of neural crest 
origin, the degeneration of dermal nerves and nerve endings could play a role in the 
development of vitiligo. 
Another histological investigation searched for a relationship between vitiligo 
pathogenesis and Merkel cells, a type of neuroendocrine cell. These cells are localized to 
the epidermis and are more abundant in sun-exposed areas (Moll et al., 1990, Lacour et al., 
1991). Moreover, these cells are continuous with nerve fibers. Bose investigated biopsies 
from five patients with stable vitiligo. Lesions and adjacent normal skin samples were 
compared to biopsies from unaffected control skin from normal subjects. All five patients 
had Type A vitiligo (i.e., their lesions did not follow a strict dermatomal pattern). The 
monoclonal antibody TROMA 1 was used for indirect immunofluorescence study of the 
biopsies to detect the presence of Merkel cells. Bose (1994) found that in the adjacent 
normal skin biopsies of vitiligo patients, and in the normal skin biopsies of healthy 
controls, that TROMA 1 bound to an average of five Merkel cells on the basement 
membrane of hair follicles and skin. There was no binding of TROMA 1 to Merkel cells 
evident in lesional skin biopsies. Bose thereby observed the loss of Merkel cells in 
vitiliginous skin. Toxic metabolites resulting in melanocyte destruction could lead to the 
diminished number of Merkel cells, or an alternative mechanism may exist between 
melanocytes and Merkel cells that results in the loss of Merkel cells and eventually 
melanocyte loss.  
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3.3 The role of the sympathetic nervous system in depigmentation 
The role of the sympathetic nervous system in tyrosinase activity and pigmentation was 
performed in an animal study. Laties and Lerner (1975) took twenty-eight brown-eyed, 
Dutch belted rabbits and resected the superior cervical ganglion on one side in 10, and 
interrupted the preganglionic nerve trunk in the remaining 18. Regardless of which 
sympathectomy procedure was used, the researchers considered signs of ptosis and miosis 
as indicators of successful surgical outcomes (i.e., loss of sympathetic nervous system 
activity). They found that in all of the animals that survived longer than two months, the 
color of the eye ipsilateral to the surgery lightened compared to the other eye. The 
researchers also completed an assay for tyrosinase activity in the iris tissue and found that 
following both types of surgery, tyrosinase activity was diminished. This loss of enzyme 
activity could stop melanin production and result in depigmentation. This study suggests 
that there may be sympathetic nervous system dysfunction in vitiligo.  
Wu et al (2000) sought to confirm whether the sympathetic nervous system was involved in 
the pathogenesis of vitiligo. They used laser Doppler flowmetry and iontophoresis to assess 
the level of microcirculation occurring in vitiligo lesions to in order to assess sympathetic 
nervous system activity. They examined ten patients with stable facial segmental-type 
vitiligo, and had two groups of controls. One control group contained ten stable non-
segmental-type vitiligo patients, and the other control group had ten healthy, unaffected 
individuals. All patients were matched for age and gender, and “stable” was defined as 
no new lesions or changes in present lesions in at least 3 months. They found 
approximately three times the cutaneous blood flow on the lesional side compared to that 
of the contralateral normal skin in segmental vitiligo. No such differences were found in 
the non-segmental group, or the healthy controls. When the researchers administered 
sympathetic nervous system blockers (such as propranolol), the segmental type patients 
demonstrated a dramatic decrease in blood flow, whereas the other two groups did not. 
Notably, however, when the researchers measured baseline plasma levels of 
catecholamines (specifically adrenaline and noradrenaline), and adrenoceptor (alpha and 
beta) densities on blood cells, there were no significant differences across all three groups. 
Wu et al. contend that their results further support that the nervous system is indeed 
involved in the pathogenesis of vitiligo. In particular, they found that some level of 
sympathetic nerve dysfunction exists in segmental type vitiligo, and this possibly plays an 
important role in disease onset and progression. 
3.4 Neuropeptide studies and neuronal marker investigations 
Al’Abadie et al (1994) studied neuropeptides and neuronal markers in vitiligo patients. In 12 
vitiligo patients and 7 unaffected control subjects, immunoreactivity for polyclonal general 
neuronal marker (PGP), calcitonin gene-related peptide (CGRP), vasoactive intestinal 
polypeptide (VIP), and neuropeptide Y (NPY) was tested. Compared to normal controls, 
nerve fibers reactive to NPY were increased in the marginal areas of lesions in half of the 
patients studied. In lesional biopsies, 25% of patients also showed increased reactivity for 
NPY compared to control subjects. Overall, there was locally increased NPY reactivity 
around blood vessels and in the dermis of lesions (predominantly in marginal biopsies). 
NPY is associated with noradrenaline in human dermal nerves and is known to potentially 
exert a local autonomic effect. Furthermore, it is also a potential modulator of the 
sympathetic response. These results suggest that changes in neuropeptide reactivity in 
vitiligo patients could be a factor in the onset or progression of the disease.  
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Lazarova et al (2000) carried out a similar study several years later. This study employed 
indirect immunofluorescence techniques to identify the immunoreactivity of nerve fiber 
endings in the skin to neuropeptides and found similar findingss as Al’Abadie et al reported 
in 1994. In affected skin samples, NPY was most intensely reactive; however, Lazarova et al 
found that CGRP was also increased, although not as significantly. Both studies suggest that 
neuropeptides play a role in vitiligo pathogenesis. Lazarova et al postulated that a 
precipitating factor, for example, stress, causes a significant secretion of neuropeptides like 
NPY, which subsequently set off other reactions that trigger the onset of vitiligo.  
Furthermore, Yehuda et al (2005) examined the relationship between the neuronal marker 
NPY and stress in vitiligo. The trial included thirty-four male veterans, eleven of whom 
were not exposed to any military trauma, eleven exposed (to military trauma), veterans 
without post-traumatic stress disorder (PTSD), and twelve veterans who were exposed with 
PTSD. Plasma NPY levels were determined. Upon regression analysis of collected data, high 
NPY levels were associated with symptom recovery and effective coping with trauma or 
stress. This finding suggests that NPY may have a protective role in stress exposure. 
Rateb et al (2004) studied the role of nerve growth factor (NGF), a neuropeptide hormone, in 
a cohort of 20 vitiligo patients and 10 non-vitiliginous control subjects. All but two vitiligo 
patients had widespread disease. NGF is an amino acid peptide hormone that is required for 
sympathetic nervous system function (Lewin et al., 1996). Rateb et al (2004) measured NGF 
levels in the lesions and non-affected skin in vitiligo patients and in the skin of control 
subjects. They found significantly increased levels of NGF in the lesional skin of affected 
patients when compared to non-lesional and control skin. At the same time, NGF levels 
were still higher in the non-lesional skin of vitiligo patients when compared to control skin 
samples. Thus, NGF may play a neurochemical role in the pathogenesis of vitiligo, and its 
presence could be an important factor in the maintenance or destruction of melanocytes 
(David, 2001 as cited in Rateb et al., 2004).  
Peters et al (2004) investigated the role of NGF in stress-induced neurogenic inflammation 
using a mouse model in which mice were subjected to sonic stress and then examined for 
subsequent hair growth termination. Skin tissue NGF levels and NGF receptors TrkA and p75 
neurotrophin receptor (p75NTR) were measured using fluorescence immunohistochemistry. 
They found that stress upregulates NGF expression in hair follicles. Stress also increased 
expression of the low affinity p75NTR NGF-receptor and decreased that of the high affinity 
TrkA receptor. Using retrograde tracing, the researchers also found that NGF injections, which 
mimic stress, increased the proportion of Substance P neurons in the dorsal root ganglia. Since 
Substance P is involved in neurogenic inflammation, their overall findings suggest that stress-
induced NGF expression can set off neurogenic inflammation.  
Another group of neuropeptides relevant to vitiligo includes catecholamines. Morrone et al 
(1992) measured catecholamine metabolite levels in the urine of vitiligo patients. The 
researchers argued that because many vitiligo patients associate their disease onset to a 
stressful event or injury, and that these situations often result in presynaptic release of 
catecholamines (namely dopamine, norepinephrine and epinephrine); therefore, 
catecholamines could play an important role in the pathogenesis of vitiligo. In particular, 
they measured the metabolites homovanillic acid (HVA), vanilmandelic acid (VMA), 3-
methoxytyramine (MT), normetanephrine (NMN), metanephrine (MN), 3,4-dihydroxy 
mandelic acid (DOMAC), and 3,4-dihydroxy phenylacetic acid (DOPAC) in 24-hour urine 
samples. Their population included 150 patients and 50 healthy controls. Of the 150 patients, 
15 had generalized vitiligo, 50 had segmental type, and 85 had acrofacial vitiligo. Three 
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groups were then created. Group 1 had 8 segmental and 18 acrofacial patients, all with early 
active phase (early onset) vitiligo or with disease progression (as indicated by number and 
size of lesions). The second group included patients who had no new lesions in the last 4-8 
months (5 generalized, 10 segmental, and 19 acrofacial patients). The third and last group of 
patients had stable vitiligo lesions for 1-5 years. Twenty-four-hour urine collections from all 
groups showed that the first and second groups had HVA (a dopamine derivative) levels 4 
to 10 times higher than controls, and VMA (an epinephrine and norepinephrine derivative) 
levels up to 3 times higher than controls. The long-term stable vitiligo patients showed no 
significant difference in any of the measured catecholamine metabolites when compared to 
controls. Overall, the results demonstrate that HVA and VMA urinary levels correspond to 
the onset and progressive active phases of vitiligo, regardless of the way the disease is 
distributed (segmental, generalized, or acrofacial). Morrone et al postulated from their 
results that the high urinary levels of HVA and VMA are markers of increased 
catecholamines in the circulation, and catecholamines are increased as a result of stress at 
the onset of disease. They also asserted that as patients grow accustomed to the lesions, their 
stress levels associated with the disease decreases, and consequently, so do levels of 
circulating catecholamines and urinary metabolites. This lends some support to the neural 
hypothesis, i.e., that neurotransmitters may play a central role in the pathogenesis of vitiligo. 
They suggest that increased levels of catecholamines at autonomic nerve endings in the skin 
could be cytotoxic to melanocytes either directly or indirectly through their metabolites. 
Notable metabolites include melanotoxic phenols that can bind tyrosinase and interfere with 
melanogenesis. Morrone et al (1992) also suggested that stressful events could result in 
catecholamine discharge. These catecholamines could bind alpha-receptors in the skin and 
mucosa arterioles causing vasoconstriction, hypoxia, and overproduction of oxygen radicals 
that destroy melanocytes (Morrone et al, 1992).  
The Neural Theory has been investigated internationally; however, substantial evidence 
supporting this has not yet been established. Mental stress can stimulate the secretion of 
catecholamines through stimulating the hypothalamic-pituitary-adrenal axis (Morrone et al 
1992; Tolis & Stefanis, 1983; Stokes & Sikes, 1988). In addition, other neurogenic 
inflammatory mediators implicated in vitiligo pathogenesis, such as NPY (Ekblad et al., 
1984), NGF (Peters et al., 2004), and NGF receptors (Tometten et al., 2004) are also influenced 
by stress. These factors are postulated to result in melanocyte destruction via direct 
cytotoxic inflammatory or immune mechanisms. Therefore, pharmacologic agents and non-
pharmacologic methods that alleviate mental stress and inhibit these neurogenic factors may 
be considered in the future as therapeutic targets for vitiligo.  
4. The autoimmune hypothesis 
As discussed previously, the neural hypothesis lends the most support for the pathogenesis 
of segmental-type vitiligo, whereas for non-segmental, or “generalized” vitiligo, the 
pathogenesis may be better explained by autoimmune mechanisms. One of the most 
apparent correlations between vitiligo and autoimmunity is the finding that patients with 
vitiligo often have autoimmune comorbidities. Another common finding in support of this 
hypothesis is that vitiligo often responds to immunosuppressive treatments (Lepe et al., 
2003). In this section, the pertinent research findings and arguments in support of the 
autoimmune theory of vitiligo pathogenesis will be discussed. The mechanisms of immunity 
are humoral (antibody-mediated), cell-mediated, or mediated by cytokines. Autoantibodies 
and their respective target cells are also relevant to the pathogenesis of vitiligo.  
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4.1 The role of autoantibodies, the humoral immune system and concomitant 
autoimmune disease 
Kemp et al (2010) searched for autoantibodies against tyrosine hydroxylase (TH, an enzyme 
required for the production of catecholamine neurotransmitters) (Lewis et al., 1993 as cited 
Kemp et al., 2010). The researchers obtained sera from non-segmental vitiligo patients, 8 
segmental patients, and 91 individuals with other autoimmune diseases (not including 
vitiligo), such as autoimmune thyroid disease, Addison’s disease, and systemic lupus 
erythematosus (SLE). They also examined the sera of twenty-eight healthy controls with no 
history of autoimmune disease or vitiligo. Sera were tested for TH antibodies using a 
radioimmunoassay (RIA). They found that 23% of the patients with non-segmental vitiligo 
were positive for TH antibodies, whereas all control subjects and segmental-type patients 
were negative for TH antibodies. They also found a significant increase in TH positivity in 
patients with active disease over those with stable disease (defined here as no new or 
changing lesions in the previous 6 months). To confirm whether the TH antibodies were 
specific for TH, the researchers used absorption assays for several enzymes and found that 
the TH antibodies did not cross-react with phenylalanine hydroxylase (PAH) or tryptophan 
hydroxylase (TPH). Furthermore, in non-segmental patients, antibodies against MCHR1 
(melanin-concentrating hormone receptor 1) and tyrosinase (Kemp et al., 2010) were noted. 
These findings suggest autoimmunity plays a role in the development and activity level of 
non-segmental vitiligo.  
Harning et al (1991) screened sera for antibodies against pigment cell-surface antigens and 
how their presence reflected vitiligo disease activity. Twenty-four vitiligo patients (10 with 
active and 14 with inactive disease), and nineteen healthy individuals who served as 
controls were included in this study. Active disease was defined as new or progressive 
disease within the 3 months prior to serum extraction. The researchers used a live-cell 
enzyme linked immunoabsorbant assay (ELISA) to detect relevant antibodies and their 
subtypes. They reported that the average level of pigment cell antibodies was notably 
greater in patients with active disease than in patients with inactive disease or in the 
controls, and there was no significant difference between inactive patients and controls. 
Results also indicated that immunoglobulin G (IgG)- and immunoglobulin M (IgM)-based 
pigment cell antibodies were found in 80% of active vitiligo patients. The control subjects 
and the inactive vitiligo patients demonstrated no IgG levels; however, 21% of inactive 
vitiligo patients and 16% of controls had notable levels of IgM. Immunoglobulin A (IgA) 
pigment cell antibodies were found in several individuals from the inactive and control 
groups – albeit in low levels (and the levels were not significantly different between these 
two groups). Harning et al demonstrate a relationship between pigment-cell antibody levels 
and vitiligo disease activity. This supports the idea that an autoimmune-mediated 
interaction with pigment cells exists in the pathogenesis of vitiligo.  
As discussed earlier, vitiligo often occurs alongside other autoimmune disorders. Ingordo et 
al (2011) sought to decipher this relationship further by measuring circulating 
autoantibodies in a population of young southern Italian males. A total of 60 male vitiligo 
patients were included in the study. The average age was 19 years old, with an age range of 
18-21. Circulating antibodies were found in 42.5% of these patients. Specifically, anti-
thyroglobulin antibodies were detected in 27.5%, anti-thyroperoxidase in 22.5%, and anti-
smooth muscle antibody in 17.3%. These antibodies are typically related to thyroid disease 
and other autoimmune diseases. They are of interest because vitiligo and thyroid disease are 
often associated with one another. In this study, only 5% of all patients presented with overt 
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thyroid disease. Their results, when taken along with patient histories and analyzed using 
Fisher’s exact test and T-testing, revealed that circulating autoantibodies, in particular anti-
thyroid antibodies, were correlated only with recent onset of vitiligo. Their results showed 
that, in vitiligo patients, autoantibodies are often present without overt autoimmune 
disease, and that their presence, albeit related to onset, is unrelated to the course or extent of 
the vitiligo itself. Circulating autoantibodies thus may have an early role in the mechanisms 
ultimately leading to melanocyte destruction.  
Similarly, Uncu et al (2011) examined the incidence of thyroid disorders in children with 
vitiligo using thyroid-specific tests. Fifty children with vitiligo (with an average age of 9.5 
years, 26 males and 24 females) and fifty control children (25 males and 25 females, with an 
average age of 8.6 years and no history of autoimmune disorders) were examined for serum 
levels of free triiodothyronine, free thyroxine, (T3 and T4 respectively), TSH and antibodies 
to thyroperoxidase and thyroglobulin. All major subtypes of vitiligo were included in the 
patient population; however, generalized vitiligo was the most common. None of the 
subjects had overt thyroid disease; however 8% of the vitiligo group tested positive for 
autoimmune thyroiditis. No healthy controls were diagnosed with autoimmune thyroiditis. 
In addition, the researchers concluded that having concomitant autoimmune thyroiditis was 
more likely if the patient was female and if the duration of vitiligo was longer. This study 
further supports the association of vitiligo with autoimmune thyroid dysfunction, and that 
vitiligo may be caused by an autoimmune pathomechanism. 
The humoral immune system likely plays roles in the autoimmune pathogenesis of 
vitiligo. The potential targets of these antibodies have been studied. A specific cell-surface 
target worthy of discussion is the melanin concentrating hormone receptor 1 (MCHR1). 
Using IgG from the sera of vitiligo patients and phage-display technology with a 
melanocyte complementary deoxyribonucleic acid (cDNA) phage-display library, Kemp et 
al (2002) first identified MCHR1 as a novel target for vitiligo autoantibodies in 2002. In 
total, 55 patients with vitiligo were enrolled, 41 with no autoimmune disorders, and 14 
with one or more. Using radio-binding assays, immunoreactivity against MCHR1 was 
confirmed in sera from all of the patients. Antibodies to MCHR1 were found in 16.4% of 
the patients with vitiligo, whereas control sera exhibited no reactivity. Although this 
suggests that MCHR1 antibodies have a high disease-associated specificity for vitiligo, 
how they arise is unknown, and no obvious correlations between the presence of the 
antibodies and age of onset, gender, duration, subtype, or existence of concomitant 
autoimmune disease was determined. Normally, melanin concentrating hormone (MCH) 
binds MCHR1 (a G-protein-coupled receptor) to mobilize intracellular calcium (Chambers 
et al., 1999) and acts as an antagonist of α-melanocyte-stimulating hormone (α-MSH). 
Studies by Hoogdijn et al (2001) suggest that MCH partially inhibits the induction of 
melanogenesis by α-MSH in human melanocytes (Hoogdijn et al., as cited in Kemp et al., 
2002). Thus, signaling pathways involving MCHR1 could be involved in melanocyte 
regulation and melanin production (Kemp et al., 2002). 
Although MCHR1 was successfully identified as a target, how the antibodies interacted at 
this target was not elucidated. Gottumukkala et al (2006), sought to determine whether 
MCHR1 autoantibodies activate or block the MCHR1 response to MCH by studying nine 
vitiligo patients with MCHR-binding autoantibodies, nine vitiligo patients without these 
autoantibodies, ten patients with SLE (due to their tendency to exhibit notable autoantibody 
reactivity), and twenty healthy individuals ascontrols. IgG samples were taken from all 
participants, and fluorometry was used to detect intracellular calcium levels which would 
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reflect MCHR1 activity. No control or SLE patient samples blocked MCHR1 receptor 
activity; however 56% of the IgG samples of vitiligo patients inhibited the function of 
MCHR1. No MCHR-activating autoantibodies were detected in any participant. The 
researchers found no correlation between the presence of MCHR-autoantibodies and vitiligo 
subtype, activity, age of onset, duration, or presence of concomitant autoimmune disease. 
This demonstrates that MCHR1-binding autoantibodies can block the function of MCHR1, 
and MCHR1 is a relevant B-cell auto-antigen in vitiligo (Gottumukkala et al., 2006). 
4.2 The role of cell-mediated immunity in vitiligo 
Le Poole et al (1996) sought to elucidate what specific types of immune mechanisms were 
taking place in vitiligo. The perilesional skin of patients suffering from inflammatory vitiligo 
was evaluated. Inflammatory vitiligo is a relatively rare subtype of vitiligo in which 
perilesional skin is red, itchy, and irritated, and inflammation progresses outwards into 
unaffected skin. Consequently, the investigators hypothesized that the inflammatory 
process may play a role in the elimination of melanocytes. Thus, using antibodies, they 
examined the inflammatory infiltrates of the perilesional skin and determined their 
composition. Specifically, they used antibodies for melanocytes, T-cells (CD2, CD3, CD4, 
and CD8), Langerhans cells, and macrophages (CD36 and CD68). Each of these components 
was assessed immunohistologically by single and double immunostaining of the 
perilesional biopsies. Three inflammatory vitiligo patients were biopsied and results were 
compared to healthy control skin. The researchers found that melanocyte densities were 2.5 
times greater in control skin than in the pigmented non-lesional skin of vitiligo patients. In 
perilesional skin, 66% of the patients demonstrated a marked decrease in melanocyte 
density when compared to non-lesional skin. CD3 staining of T cells was significantly 
greater in perilesional skin when compared to non-lesional or lesional skin. Also in 
perilesional skin, T cell infiltrates were substantially increased in the epidermal 
compartment and mostly concentrated to where melanocyte destruction occurs (at the 
epidermal basal layer). The epidermis-infiltrating T cells found in perilesional skin 
demonstrated an increased CD8:CD4 ratio, and increased interleukin-2 receptor (IL-2) 
expression. Interestingly, patients with generalized vitiligo have also been found to have an 
increased CD8:CD4 T cell ratio.  
This finding suggests that the destruction of melanocytes could be cytotoxic CD8 T-cell 
mediated. All of the vitiligo patients also exhibited perilesional HLA-DR expression (MHC 
class II receptor), particularly along basal and suprabasal keratinocytes, which could be 
attributed to local T cell reactivity. Finally, Le Poole et al found that CD68+OKM5-type 
macrophages were more abundant in lesional and non-lesional skin when compared to 
controls, whereas the CD36 subset of macrophages were more abundant in control skin. 
From an autoimmune perspective, these results suggest that a melanocyte-specific immune 
reaction, most notably involving T cells, may play a role in the evolution of vitiligo. 
4.3 The role of cytokines in vitligo 
The immune system involves a complex interplay of many factors beyond lymphocytes and 
antibodies; this includes cytokines, which may also play a role in the development of 
vitiligo. Tacrolimus (FK-506 or Fujimycin) is an immunomodulatory drug thought to inhibit 
T cell activation and consequently diminish the production and secretion of pro-
inflammatory cytokines (Schreiber & Crabtree, 1992 as cited in Grimes et al., 2004). Grimes et 
al. (2004) performed a twenty-four week study that tested the effectiveness of 0.1% 
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tacrolimus ointment on nineteen patients with generalized vitiligo. The pre- and post-
treatment cytokine expression in lesional and non-lesional skin compared to the expression 
in skin of normal controls was also assessed. A topical preparation of tacrolimus was 
applied twice daily for the 24-week study duration. Punch biopsies were performed at 
baseline from depigmented, non-sun-exposed lesional skin and adjacent non-lesional skin, 
and similar biopsies were taken from non-sun-exposed control skin. Following the 24-week 
treatment period, repeat biopsies were performed. A total of nineteen patients completed 
the study. Some level of repigmentation occurred in 89% of patients, most of which occurred 
in the face and neck regions. Overall, 68% of patients achieved between 76% and 100% 
repigmentation. In terms of cytokine expression, at baseline, both the involved and 
uninvolved skin of vitiligo patients demonstrated significantly increased expression of IL-
10, IFN-γ, and TNF-α compared to expression in control skin. Post-treatment, the only 
significant difference was that expression of TNF-α was decreased compared to baseline in 
both lesional and non-lesional skin of the vitiligo patients.  
These findings suggest that a cytokine imbalance is likely to be involved in the pathogenesis 
of vitiligo, and that the apparent suppression of TNF-α by tacrolimus may facilitate 
repigmentation. It is important to consider that repigmentation with tacrolimus was most 
notable in sun-exposed areas (i.e., the face and neck). Therefore, it could be suggested that 
the suppression of cytokines, namely TNF-α, facilitates UV-stimulation of melanogenesis 
and ultimately, the repopulation of melanocytes in vitiliginous skin (Grimes et al., 2003).  
Considering that TNF- α and IFN- γ are both T helper cell-1 (Th1) cytokines, Taher et al 
(2006) suggest that vitiligo is mediated by the Th1 response. They also argue that tacrolimus 
could promote repigmentation by potentially suppressing the Th1 response via 
upregulating the immunosuppressive Th2 cytokine, IL-10 (Taher et al., 2006). The 
researchers measured Th2-related cytokine IL-10 levels before and after treating twenty 
vitiligo patients with tacrolimus. Following three months of treatment, of the seventeen 
patients who completed the study, all experienced a significant decrease in lesion size, and 
all noted follicular repigmentation. On average, patients experienced a 41% decrease in the 
size of their lesions after the course of the treatment. In addition, IL-10 levels were 
significantly increased in lesional skin post-treatment, compared to normal control skin and 
lesional untreated skin. These results further supported tacrolimus as an effective vitiligo 
treatment. Bassiouny and Shaker (2011) further investigated the putative role of cytokines in 
vitiligo by studying interleukin 17 (IL-17). IL-17 is a cytokine that interacts with many cell 
types: keratinocytes, macrophages, and fibroblasts, amongst others. Furthermore, IL-17 
works to activate the production of other cytokines, including IL-1 and IL-6, and can 
potentiate other local inflammatory mediators like TNF-α (Kolls & Linders, 2004, as cited in 
Bassiouny & Shaker, 2011). Using a similar ELISA technique as Harning et al., the Bassiouny 
research team took a population of thirty patients with vitiligo and twenty healthy controls 
and examined their sera and tissue for the cytokine IL-17. They found increased levels of IL-
17 in both the lesional skin and sera of the vitiligo patients, compared to that of the controls. 
In addition, they found a statistically significant positive correlation between disease 
duration and the level of IL-17 in both the sera and tissue samples. Although the exact 
function of IL-17 overexpression is unclear, this study affords further support for cytokine-
involvement in the development of vitiligo (Bassiouny & Shaker, 2011).  
The autoimmune hypothesis for vitiligo is has provided the basis for a vast number of 
experimental designs and studies. The immune system is complex, involving cell-mediated 
and humoral mechanisms – both of which appear to play roles in the manifestation of 
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vitiligo. Identifying pathways involved in the immune reactions in vitiligo will help in 
understanding the cause of vitiligo and pave the way for developing specific immune 
targets to combat the disease.  
5. The reactive oxygen species model 
The theory that oxidative stress is a cause for vitiligo suggests that patients with vitiligo 
have an imbalanced redox (reduction-oxidation) state of the skin, resulting in the excess 
production of reactive oxygen species (ROS, e.g., H2O2). These disturbances and ROS 
accumulation can have toxic effects on all components of the cell (e.g., proteins, lipids), and 
could potentially result in the destruction of melanocytes creating the depigmented macules 
observed in vitiligo (Khan et al., 2009).  
5.1 Establishing the redox status of vitiligo patients 
An early study relevant to this theory examined the anti-oxidant defense enzymes catalase 
(CAT), glutathione reductase (GR), and thioredoxin reductase (TR) in lesional and non-
lesional skin using suction blisters from vitiligo patients (Schallreuter et al., 1991). They 
found that TR levels were similar between patients and healthy controls; however, CAT 
levels were significantly decreased in both lesional and non-lesional skin of patients 
compared to healthy controls. Lastly, GR levels were also notably higher in patient skin 
compared to controls, with a significantly higher amount in the non-lesional, or pigmented 
skin of the patients compared to levels in the lesional skin. Since GR can facilitate some level 
of oxygen metabolism, the authors suggest that GR is upregulated as an attempt to 
compensate for the lack of catalase. Catalase is involved in oxygen metabolism, and these 
results suggest that catalase levels are decreased throughout the epidermis (spanning both 
affected and unaffected skin) in vitiligo patients. Thus, it is probable that oxygen 
metabolism is defective in vitiligo (Schallreuter et al., 1991).  
Ines et al (2006) examined the serum of thirty-six vitiligo patients (eighteen with stable and 
eighteen with active disease), and forty healthy controls for markers of redox status 
including malondialdehyde (MDA), selenium, vitamins E and A, and the erythrocyte 
activities of glutathione peroxidase (GPx), superoxide dismutase (SOD) and CAT. SOD 
scavenges superoxide radicals and reduces their toxicity (converts O2- to O2 and H2O2) and 
catalase converts hydrogen peroxide (H2O2) to oxygen (O2) and water (H2O) (Ines et al., 
2006). MDA is a product of lipid peroxidation and is an indicator of oxidative stress (Latha 
& Babu, 2001, Yildirim et al., 2004). Selenium is required for GPx activity and vitamins E and 
A are important in antioxidant activity. Ines et al found that SOD and MDA activity as well 
as serum selenium were increased in both stable and active disease, however, all were 
maximally increased in the active disease state. Erythrocyte CAT activity and serum vitamin 
A and E levels were not significantly different from controls. The researchers suggest that 
enhanced SOD activity results in the accumulation of H2O2. Furthermore, GPx is a 
downstream enzyme that detoxifies H2O2, and GPx levels were found to be decreased in 
vitiligo patients, which could compound H2O2 accumulation (Ines et al., 2006).  
Ines et al (2009) then sought to determine if disease activity was associated with oxidative 
stress at the tissue level. Tissue levels of MDA, CAT, SOD, and GPx from 10 stable and 10 
active vitiligo patients were compared to levels found in twenty healthy volunteers. Overall, 
SOD, GPx, and MDA levels were all increased in both active and stable disease with 
consistently higher increases in the active group. Conversely, CAT activity was significantly 
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decreased in both active and stable disease with a more notable decrease in the active group. 
This suggests that increased SOD activity in vitiligo patient tissue could be an adaptation to 
increased oxidative stress; however, the increased SOD ultimately results in H2O2 
accumulation that can not be broken down by CAT because it is present in subnormal levels 
(Ines et al., 2009).  
Ines et al had some conflicting results between the 2006 and 2009 studies. The latter found 
decreased CAT levels and increased GPx levels in tissue, whereas previously, CAT was 
unchanged and GPx was decreased in patient serum. To substantiate the more recent Ines et 
al findings, Yildirim et al (2004) also found increased SOD, MDA, and GPx when examining 
the tissue of vitiligo patients. In addition, Khan et al (2009) found increased MDA, but 
significantly lower levels of SOD, GPx, and non-enzymatic antioxidant agents vitamins C 
and E in vitiligo patient serum. From these results, GPx is arguably increased in tissue, but 
its activity is decreased in the serum of vitiligo patients. The low SOD activity found by 
Khan et al is controversial, considering that the other studies discussed all found increased 
SOD activity. To reinforce this assertion, Sravani et al (2009) found statistically significant 
increases in SOD and CAT levels in both lesional and non-lesional skin of vitiligo patients 
compared to levels measured from skin from healthy controls. Furthermore, they found that 
CAT was decreased in both vitiligo skin typescompared to controls (Sravani et al., 2009). 
Thus, the results from measuring similar markers vary somewhat from study to study. Khan 
et al suggested that these discrepancies could be due to differences between serum and 
tissue levels, duration, and activity of disease, as well as differences in laboratory techniques 
(Khan et al., 2009). Nonetheless, when compared to controls, markers of oxidative stress in 
vitiligo patients are found at aberrant levels indicating that the balance between ROS and 
the anti-oxidant defense system is disrupted.  
5.2 Characterizing the redox disruption in vitiligo 
Dell’Anna et al (2001) suggested that the source of this disruption lies at the level of 
mitochondria. The research team retrieved and examined red blood cells (RBCs) and 
peripheral blood mononuclear cells (PBMCs) from forty non-segmental vitiligo patients and 
forty age- and sex-matched controls. They assessed the PBMCs for ROS generation using a 
2’,7’-dichlorofluorescein diacetate (DCFH-DA) assay and flow cytometry analysis. They 
found significantly higher ROS generation in cells from active vitiligo subjects. Dell’Anna et 
al suggested that this ROS hyperproduction could be caused by opening of mitochondrial 
permeability transition pores (PTPs). They found that when they added a PTP inhibitor 
cyclosporin A, (CsA) to the cells, the DCFH-DA staining significantly decreased in the active 
vitiligo patients, reinforcing the notion that excess ROS production resulted from PTP 
opening at the level of mitochondria (Dell’Anna et al., 2001).  
To further characterize the redox imbalance in vitiligo and changes of mitochondria, blood 
samples were taken from fifty vitiligo patients (thirty-five with active and fifteen with stable 
vitiligo) and thirty healthy controls (Dell’Anna et al., 2003). They measured the oxidative 
stress markers CAT, reduced glutathione (GSH), and SOD, and similar to previous research, 
found decreased CAT and GSH and increased SOD levels. Consequently, the SOD/CAT 
ratio was significantly higher in active disease and unchanged in stable and normal patients. 
ROS generation was significantly higher in active disease only. ROS levels correlated with 
the SOD/CAT ratio in controls and stable patients; however, the ratio was found to be 
inversely related to ROS activity in active patients. Thus, the researchers contend that excess 
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ROS production is an established phenomenon in vitiligo and when the disease is stable, 
this excess is balanced out by the body’s cellular antioxidant system. Conversely, when the 
disease is active, and an oxidative stimulus is present, cells increase their ROS production 
and the redox balance is lost (Dell’Anna et al., 2003).  
In the same study, due to the function of mitochondria as the main intracellular source of 
ROS, mitochondrial function was also evaluated (Dell’Anna et al., 2003). The researchers 
found a significant decrease in membrane potential across mitochondria in both active and 
stable vitiligo patients compared to controls. They also assessed the electron transport chain, 
or ETC, with a series of tests involving inhibitors of each complex. They found that PBMCs 
from vitiligo patients are susceptible to rotenone, an inhibitor of complex I. They also 
evaluated the Krebs cycle efficiency in mitochondria, and found the mitochondrial isoform 
of malate dehydrogenase activity was notably increased in vitiligo patients. These findings 
further support the assertion that mitochondrial dysfunction is involved in the pathogenesis 
of vitiligo (Dell’Anna et al., 2003).  
At the time, the cause of ETC impairment and mitochondrial dysfunction was yet to be 
elucidated. Thus, Dell’Anna et al investigated further using punch biopsies from five vitiligo 
patients and five healthy controls, and focused this study on characterizing lipid membranes. 
Confocal microscopy and fluorescence-activated cell sorting (FACS) revealed that epidermal 
primary vitiligo melanocytes had significant membrane peroxidation and that the pattern of 
fluorescence retrieved was specifically suggestive of the involvement of mitochondrial 
membranes (Dell’Anna et al., 2007). To investigate the mitochondrial membrane changes more 
thoroughly, the content and transmembrane portion of cardiolipin, or CL was assessed. CL is a 
phospholipid that has four fatty acyl chains that is associated with mitochondria and with 
proteins that conduct oxidative phosphorylation (Haines & Dencher, 2002). There was a 
reduced percentage of CL and a modified distribution of CL in the melanocyte mitochondria 
of vitiligo patients, particularly in comparison with particulary in comparison with controls 
controls. Furthermore, to assess the ETC, they performed a semiquantitative analysis of 
complex 1 (CxI) activity and found CxI was decreased in melanocytes from vitiligo subjects 
when compared to the controls. These results provide a plausible mechanism for vitiligo 
pathogenesis in which there is a primitive defective arrangement of membrane lipids (namely 
altered CL distribution) that results in impaired ETC activity. Hyperproduction of ROS ensues, 
and the redox imbalance ultimately causes melanocytes destruction (Dell’Anna et al., 2007).  
5.3 The role of tetrahydrobiopterin recycling and other indicators of oxidative stress 
in vitiligo  
The accumulation of hydrogen peroxide (H2O2) in the skin of vitiligo patients is an important 
finding, with many implications. One particular cellular pathway affected by H2O2 involves 
tetrahydrobiopterin. Tyrosinase is a hallmark enzyme in the synthesis of melanin (Prota, 1992). 
L-tyrosine is formed from L-phenylalanine by the enzyme phenylalanine hydroxylase (PAH). 
The essential cofactor for this process is 5,6,7,8-tetrahydrobiopterin or 6BH4. Defective 
recycling of 6BH4 yields excess levels of 7BH4, which is an inhibitor of PAH. This uncoupling 
of PAH and presence of 7BH4 was found in suction blister material from the skin of vitiligo 
patients (Schallreuter et al., 1994, 1998). Kowlessur et al (1996) also found that 7BH4 production 
can lead to the formation of H2O2. To investigate this defective recycling of 6BH4 evident in 
vitiligo, Haase et al (2004) studied the enzyme dihydropteridine reductase, or DHPR, which is 
responsible for the final steps in normal 6BH4 recycling. They examined whole blood samples 
from twenty-seven untreated vitiligo patients and eight unaffected controls. The researchers 
www.intechopen.com
 
The Pathogenesis of Vitiligo 
 
47 
also determined the effect of H2O2 concentration on DHPR activity. They found that 
concentrations of H2O2 greater than 30 µM decreased DHPR activity, whereas concentrations 
less than 30µM activated or increased DHPR activity. From this relationship it can be 
suggested that the accumulation of H2O2 through its concentration-dependent association with 
DHPR, results in defective 6BH4 recycling. They confirmed the concentration-dependent 
association between H2O2 and DHPR using Fourier transform-Raman spectroscopy. 
Interestingly, when patients were treated with topical pseudocatalase (low-dose narrow-band 
ultraviolet B-activated pseudocatalase PC-KUS – a treatment to remove epidermal H2O2), their 
whole blood DHPR activities normalized. This finding suggests that the removal of epidermal 
H2O2 affects systemic H2O2 balance. Overall, this illustrates the role ROS, namely H2O2, plays 
in the pathogenesis of vitiligo.  
Schallreuter et al considered the effect of H2O2 on acetylcholinesterase (AchE). This enzyme 
was of interest because AchE levels were found to be lower in patients with vitiligo when 
compared with healthy controls, suggesting cholinergic involvement in the disease (Iyengar, 
1989 as cited in Schallreuter et al., 2004). Skin biopsies from sun-unexposed areas from four 
healthy controls and four vitiligo patients. Similar to the findings of Iyengar, Schallreuter et 
al found that depigmented vitiligo skin showed marked decreases in AchE levels compared 
to controls while repigmenting patients treated with PC-KUS demonstrated an increase in 
AchE throughout the epidermis. Untreated depigmented skin showed very little catalase 
activity, and PC-KUS-treated skin showed significantly higher catalase expression 
throughout the epidermis compared to controls. Thus, H2O2 levels were also found to have a 
concentration-dependent influence on AchE, i.e., low H2O2 concentrations (approximately 
10-6M or mol/L) activate AchE whereas high concentrations (10-3M or mol/L) deactivate 
AchE (Schallreuter et al., 2004). Butyrylcholinesterase (BchE) is an enzyme that mediates the 
hydrolysis of acetylcholine. The hydrolysis reaction is one of the rate-limiting steps in 
cholinergic signal transduction (Rakonczay & Brimijoin, 1988 as cited in Schallreuter et al., 
2006). Using immunofluorescence, Schallreuter et al (2006) demonstrated that BchE is 
present in the keratinocytes and melanocytes of the human epidermis; however the BchE 
protein is much lower in skin from vitiligo patients. Upon removal of epidermal H2O2 using 
PC-KUS, vitiligo patient skin demonstrated a higher level of BchE expression than controls. 
When AchE and BchE activities were tested at the same time on the same samples, BchE 
activity levels were greater than the AchE levels. The overall decreased activities of BchE 
and AchE were apparent in both lesional and non-lesional skin of vitiligo patients 
demonstrating that the effects of H2O2 occur throughout the entire epidermal compartment.  
Considering the previous research on H2O2 accumulation in vitiligo, Shalbaf et al (2008) 
investigated xanthine oxidase (XO) as a source of H2O2 because it produces H2O2 in its 
reaction pathway. XO is found in many tissues and catalyzes the oxidative hydroxylation of 
hypoxanthine to xanthine and then xanthine to uric acid, which is accompanied by H2O2 
production (Mathews et al., 2000 as cited in Shalbaf et al., 2008). XO also oxidizes uric acid to 
allantoin, a substance that acts a marker of oxidative stress (Benzie et al., 1999). Using skin 
biopsies from vitiligo patients, the presence of XO was confirmed in melanocytes and 
keratinocytes, and regulation of XO by H2O2 was also confirmed; high concentrations of 
H2O2 inhibit the activity of XO, whereas low concentrations activate it, making the 
relationship concentration-dependent. Epidermal cell extracts from suction blister tissue 
showed that allantoin was present in patients with acute vitiligo; however, it was entirely 
absent in healthy controls. Thus, XO may be a contributor of H2O2 ROS in vitiligo.  
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The vast majority of studies germane to the ROS model recruited patients with generalized 
vitiligo, and ROS-mediated damage may be applied to the pathogenesis of non-segmental, 
generalized vitiligo until further research is done in other types of vitiligo.  
6. The melanocytorrhagy hypothesis 
Compared to the other hypotheses discussed, the melanocytorrhagy hypothesis is a 
relatively new approach to explaining the pathogenesis of vitiligo. First proposed by 
Gauthier et al in 2003, this theory describes the pathogenesis of non-segmental vitiligo (NSV) 
as from the result of “melanocytorrhagy”, or a chronic detachment and loss of melanocytes 
resulting from altered melanocytes responses to trauma and other stressors. The theory also 
attempts to tie together concepts from the theories previously discussed to create a single, 
integrated explanation of vitiligo pathogenesis, and suggests that stressors could include 
catecholamines, ROS, or autoimmune elements (Gauthier et al., 2003). 
Early studies by Le Poole et al demonstrated that melanocytes loss occurs in vitiligo lesions 
(Le Poole et al., 1993). Gauthier et al countered that although melanocyte loss is well-
established, direct demonstration of the physical destruction of melanocytes is not.  
A study supporting the concept of melanocyte loss in vitiligo was done by Tobin et al in 
2000. Twenty-seven patients with non-segmental vitiligo and ten healthy controls were 
enrolled. Seven patients received pseudocatalase treatment prior to the study, whereas 
twenty had received no previous treatment. The researchers acquired epidermal 
melanocytes and keratinocyte cultures from both lesional and non-lesional skin from vitiligo 
patients and normal controls. Light and transmission electron microscopy, as well as 
immunohistochemistry were used to evaluate the cultures for morphology. In the untreated 
vitiligo patient samples, they found vacuolation and degeneration of basal keratinocytes, 
melanocytes, and Langerhans cells. Also observed was an increased number of Langerhans 
cells in the basal layer of the epidermis near dysfunctional melanocytes, and dilated 
endoplasmic reticulum, intracellular granular debris, and fatty degeneration. Tobin et al 
attributed these changes to the oxidative stress caused by H2O2.  
More importantly, there were signs suggesting melanocytes were never entirely absent. 
Evidence of rare clear cells in the epidermis of lesional skin from vitiligo patients with 
disease duration of up to twenty-five years was observed. These cells were small and 
amelanotic, although a portion of the clear cells did contain irregular melanosomes. These 
clear cells were deemed melanocytic as they contained tyrosinase (due to positive dopa 
reactivity). Although these cells were in significantly low numbers, these findings suggest 
that melanocytes are not entirely eliminated from vitiliginous skin and that they persist in 
some form, even in long-standing disease (Tobin et al., 2000).  
Gauthier et al (2003) also purports that defective cell adhesion plays a role in the 
pathogenesis of vitiligo as the production extracellular matrix components may be altered 
by keratinocytes. Basal membrane structure dysfunction is observed in vitiligo, in particular, 
the presence of focal gaps in the basement membrane and redundant production of 
basement membrane. These alterations could weaken the basal anchoring of melanocytes, 
making them vulnerable to detachment. Trauma could exacerbate this vulnerability, leading 
to the chronic melanocyte loss that has been described as melanocytorrhagy.  
Le Poole et al argued that the protein tenascin may be involved in diminishing melanocyte 
adhesion in the pathogenesis of vitiligo. Skin biopsies of lesional and control skin were 
examined. In normal culture conditions, melanocytes most easily adhere to the extracellular 
matrix (ECM) protein fibronectin. There was an observed relationship between tenascin 
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concentration and melanocyte adhesiveness to fibronectin: an abundance of tenascin 
inhibited melanocyte to fibronectin adhesion. In general, the vitiligo patients were found to 
express higher levels of tenascin compared to controls. Whether the increased tenascin 
expression is a cause or consequence of vitiligo is unclear; however, from these results it is 
arguable that modified cellular adhesion is evident in vitiligo and could contribute to its 
pathogenesis (Le Poole et al., 1997).  
A pivotal study regarding the melanocytorrhagy hypothesis investigated how trauma could 
elicit vitiligo lesions, a process also called the Koebner phenomenon. Light and reproducible 
friction for four minutes on the forearms of eighteen patients with extensive vitiligo and on 
five healthy controls was performed. Biopsies were retrieved from the test region from all 
sets of patients at 1, 4, 24, and 48 hours after the friction was imposed. Each biopsy was 
evaluated using standard light microscopy, transmission electron microscopy, 
histochemistry, and immunohistochemistry. Control skin showed no changes; however, at 4 
and 24 hours post-friction in vitiliginous skin, some melanocytes were detached and 
apparent in suprabasal regions, i.e., the stratum spinosum, granular layer, and the stratum 
corneum. The researchers thought that vitiligo arising from the Koebner phenomenon is 
likely caused by the “transepidermal migration” observed in their study. They also 
concluded that this mechanism of melanocyte loss could provide an explanation for the 
chronic melanocyte loss evident in vitiligo, but may be instigated by another stressor other 
than friction or trauma (Gauthier et al., 2003).  
The melanocytorrhagy hypothesis was tested by recreating the initiating events leading up 
to melanocytorrhagy (Cario-André et al., 2007). Epidermis was reconstructed on dead de-
epidermized dermis (DDD) using control cells and cells from non-lesional NSV patients to 
form ”new” epidermis. Since the “new” epidermis was weakly attached to the DDD, it was 
assumed that physical friction would not be required to initiate melanocytorrhagy. The 
reconstructs were subject to a variety of stressors, for example, epinephrine, norepinephrine, 
and H2O2. Reconstructs made with non-lesional vitiligo melanocytes had fewer basal 
melanocytes when compared to reconstructs made with normal melanocytes, suggesting 
that non-lesional NSV skin is affected by the disease process.  
The reconstructs from vitiligo patients and found that 65% of the sera samples tested were able 
to induce melanocyte detachment. Epinephrine was also found to cause melanocyte 
detachment of normal and non-lesional vitiligo melanocytes; however norepinephrine had no 
effect on detachment at any concentration. Furthermore, H2O2 caused normal melanocyte…” 
(add space between H2O2 and caused) detachment, with variable effects on non-lesional 
vitiligo melanocytes. An intrinsic melanocyte defect limits melanocyte adhesion in 
reconstructed epidermis, and transepidermal migration melanocytes can occur in response to 
certain stressors (Cario-André et al., 2007). Although an early in vitro study, these results 
provide some support for the melanocytorrhagy model.  
Gauthier et al also indirectly support this theory in their early research. Their findings show 
that chronic melanocyte loss and defective adhesion could be the result of the dendritic 
function of melanocytes. Melanocyte dendrites are thought to be required for melanosome 
transfer as these processes connect melanocytes to numerous keratinocytes. Dendrites may 
play a role in melanocyte adhesion and anchoring within the basal layer of the epidermis, 
and dendrite retraction is commonly understood as the first step before melanocyte 
detachment and death. Morphologically, established vitiligo melanocytes demonstrate large 
perikaryon and “stubby” dendrites (Jimbow et al., 2000). Exposing cultures of vitiligo or 
control melanocytes to catecholamines could result in dendrite retraction and loss over a 
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twenty-four hour period. Consequently, the research group concluded that oxyradicals or 
catecholamines could cause dendrite loss, thereby compounding the transepidermal 
melanocyte loss caused by an isomorphic or the Koebner phenomenon, resulting in the 
depigmented macules observed in vitiligo. 
The melanocytorrhagy theory for the pathogenesis of vitiligo takes a new stance on how 
melanocyte loss occurs, and attempts to unify ideas from several pathogenesis theories to do 
so. Being a novel proposal, however, further research is needed to substantiate its postulations.  
7. Conclusion 
The pathogenesis of vitiligo has yet to be elucidated; however, years of research have 
provided us with a framework. A genetic predisposition to developing the disease is 
involved. The Neural Hypothesis suggests that the nervous system is involved, likely 
through the release of neurogenic factors in response to a stress event, and that these factors 
affect the survival of melanocytes. Cytotoxic and immune mechanisms are proposed to 
underlie the destruction of melanocytes through neuropeptides. The Autoimmune Theory 
argues that the loss of melanocytes observed in vitiligo is the result of an autoimmune 
reaction. The Reactive Oxygen Species Model suggests that faulty oxygen metabolism 
results in the excess production of reactive oxygen species, which causes melanocyte 
destruction. In addition, the Melanocytorrhagy Theory states that melanocyte loss occurs 
from defective cell adhesion coupled with friction or other types of stress. These 
mechanisms underlying vitiligo pathogenesis likely overlap and may vary depending on the 
type of vitiligo. Genetic factors likely precede neurogenic factors which, influenced by 
mental stress, may act via the aforementioned cytotoxic and immune mechanisms to cause 
destruction of melanocytes and resulting skin depigmentation. Future research would 
elucidate if these theories occur in a sequential fashion. Strategies targeting these pathways 
would potentially advance our therapeutic armament against vitiligo. 
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